<DOC>
	<DOCNO>NCT02350712</DOCNO>
	<brief_summary>The purpose study test study drug call patritumab . Patritumab may work combined medication approve UK treat Squamous Cell Carcinoma Head Neck ( SCCHN ) , call cetuximab , cisplatin carboplatin . It hop patritumab may benefit treat patient cancer . This study help identify much patritumab give combination cetuximab , cisplatin carboplatin . This study also show safe well tolerate patritumab medication give together .</brief_summary>
	<brief_title>A Study Using Patritumab Combination With Cetuximab Platinum Containing Therapy Patients With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically cytologically confirm recurrent disease metastatic SCCHN ( oral cavity , oropharynx , hypopharynx , larynx ) 2 . Documented disease recurrence follow prior treatment . 3 . Adult subject ≥ 18 year old . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Hemoglobin ≥ 10 g/dL 6 . Renal function , follow : Calculated creatinine clearance ≥ 60 mL/min Glomerular filtration rate ( GFR ) . 7 . Hepatic function , follow : Aspartate aminotransferase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) ( liver metastasis present , &lt; 5 x ULN ) . Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ( liver metastasis present , &lt; 5 x ULN ) . Alkaline phosphatase ≤ 2.0 x ULN ( bone liver metastases present , &lt; 5 x ULN ) . Bilirubin ≤ 1.5 x ULN . 8 . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) ≤ 1.5 x ULN . 9 . Women childbearing potential must negative serum pregnancy test perform within 14 day prior enrollment ( demanded local regulation , test may require within 72 hour prior enrollment ) . 10 . Adult subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last study dose receive . 11 . Subjects must willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % . 2 . Prior epidermal growth factor receptor ( EGFR ) target regimen . 3 . Prior antiHER2 , antiHER3 , antiHER4 therapy . 4 . Prior treatment recurrent/metastatic disease . 5 . History malignancy , except adequately treat nonmelanoma skin cancer , curatively treat insitu disease , solid tumor curatively treat evidence disease ≥ 5 year . 6 . Known history active brain metastasis . 7 . Uncontrolled hypertension ( systolic &gt; 160 mm Hg diastolic &gt; 100 mm Hg ) . 8 . Clinically significant electrocardiogram ( ECG ) change RR , pulse rate , QT , QTc QRS interval . 9 . Myocardial infarction within 1 year enrollment , symptomatic congestive heart failure ( New York Heart Association &gt; Class II ) , unstable angina , unstable cardiac arrhythmia require medication . 10 . In case platinumcontaining drug therapy radiotherapy , &lt; 6 month study drug treatment . 11 . Therapeutic palliative radiation therapy major surgery within 4 week study drug treatment . In case chemotherapy radiotherapy , &lt; 6 month study drug treatment . 12 . Participated clinical drug trial within 4 week study drug treatment . Current participation investigational procedure . 13 . Uncontrolled infection require IV antibiotic , antiviral , antifungal , know Human immunodeficiency virus ( HIV ) infection , active hepatitis B C infection , undergo medical treatment infection . 14 . Uncontrolled type 1 2 diabetes mellitus . 15 . Known hypersensitivity allergic reaction component trial treatment . 16 . Pregnant , breastfeeding , unwilling/unable use acceptable contraception . 17 . Psychological , social , familial , geographical factor would interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>